What is the difference between capmatinib and tepotinib

Capmatinib (Capmatinib) and Tepotinib (Tepotinib) are two targeted drugs for tumor treatment. They have some similarities, but there are also some differences. Here is a detailed description comparing the characteristics of these two drugs:

1. Mechanism of action: Capmatinib is a tyrosine kinase inhibitor that mainly inhibits the activation ofMET receptors on tumor cells, thereby blocking the signaling of the MET pathway and inhibiting the growth and spread of tumor cells. Tepotinib is also a tyrosine kinase inhibitor that interferes with signaling pathways mainly by inhibiting the activation of MET receptors, thereby inhibiting the proliferation and migration of tumor cells.

2. Indications: Capmatinib is mainly used to treat patients with MET gene mutations or MET overexpression in non-small cell lung cancer (NSCLC). Tepotinib is mainly suitable for patients with non-small cell lung cancer who have MET exon 14 skipping mutations (METex14).

3. Efficacy: Capmatinib has shown significant therapeutic response toMET mutation-related non-small cell lung cancer in clinical trials, and has shown good results in terms of anti-tumor activity and tolerability. Tepotinib also showed significant therapeutic responses, especially in patients with METex14 skipping mutations, with good anti-tumor activity.

4. Side effects: Common side effects of capmatinib and tepotinib include nausea, vomiting, fatigue, loss of appetite, diarrhea, etc. In addition, adverse reactions due to individual differences also exist, so the patient's condition and side effects need to be closely monitored when using these drugs.

In summary, capmatinib and tepotinib are both targeted drugs for the treatment of non-small cell lung cancer related to MET mutations. Their mechanisms of action and indications are slightly different. Clinically, both drugs have shown good anti-tumor activity and therapeutic response, but individual patient differences and side effects require close attention and monitoring.